Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How To Catch The Next Wave Of Cancer Immunotherapy

Executive Summary

Forging a development partnership with a big pharma PD-1/L1 sponsor has become a sort of beauty contest with many in the running, and small companies are best advised to invest in good preclinical datasets to make the grade, execs say at the BIO Investor Forum in San Francisco.

You may also be interested in...



Heat Biologics Tightens Belt To Reach Late-2016 Inflection Points

Biotech striving to hold on financially until it can deliver top-line data for bladder and lung cancer immunotherapy candidates, but then it will have to content with Roche entering the bladder cancer market with its PD-L1 inhibitor.

Bristol Likes What It Sees In Five Prime, Invests More In CSF1R Program

Bristol agreed to pay $350m upfront for global rights to Five Prime’s CSF1R antibody program, including FPA008, in a deal that builds on the companies’ previous clinical collaboration agreement.

Bristol Hits Sweet Spot On Checkpoint Inhibitor Combination Pricing

Decision to price combo of Yervoy and Opdivo at just 6% more than Yervoy monotherapy could set a trend for the market.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS057216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel